Cantor Fitzgerald Reiterates $105.00 Price Target for Spark Therapeutics (ONCE)

Cantor Fitzgerald set a $105.00 price target on Spark Therapeutics (NASDAQ:ONCE) in a report issued on Monday morning. The firm currently has a buy rating on the biotechnology company’s stock.

“Update at ASH in four Hemophilia A patients raises new questions on variability of factor VIII expression levels associated with SPK-8011’s treatment.”,” Cantor Fitzgerald’s analyst wrote.

A number of other research analysts have also commented on ONCE. Evercore ISI started coverage on Spark Therapeutics in a report on Wednesday, August 16th. They set an in-line rating and a $83.00 price target for the company. BidaskClub upgraded Spark Therapeutics from a hold rating to a buy rating in a report on Saturday, August 26th. Barclays started coverage on Spark Therapeutics in a report on Wednesday, September 6th. They set an overweight rating and a $104.00 price target for the company. Royal Bank of Canada started coverage on Spark Therapeutics in a report on Thursday, September 14th. They set an outperform rating and a $100.00 price target for the company. Finally, SunTrust Banks reiterated a buy rating and set a $95.00 price target (up from $85.00) on shares of Spark Therapeutics in a report on Monday, September 25th. Two equities research analysts have rated the stock with a sell rating, five have given a hold rating and fifteen have given a buy rating to the stock. The stock presently has a consensus rating of Buy and an average target price of $76.19.

Shares of Spark Therapeutics (NASDAQ ONCE) traded up $1.15 during mid-day trading on Monday, hitting $45.91. The stock had a trading volume of 1,895,700 shares, compared to its average volume of 481,123. Spark Therapeutics has a one year low of $41.06 and a one year high of $91.75.

Spark Therapeutics (NASDAQ:ONCE) last issued its quarterly earnings results on Tuesday, November 7th. The biotechnology company reported ($1.90) EPS for the quarter, missing analysts’ consensus estimates of ($1.79) by ($0.11). Spark Therapeutics had a negative return on equity of 60.01% and a negative net margin of 1,090.11%. The business had revenue of $1.90 million for the quarter, compared to analyst estimates of $1.40 million. During the same quarter last year, the firm earned ($1.07) earnings per share. The firm’s quarterly revenue was up 45.8% compared to the same quarter last year. equities research analysts anticipate that Spark Therapeutics will post -7.6 EPS for the current year.

In other Spark Therapeutics news, Director Hospital Of Philade Children’s sold 1,000,000 shares of the company’s stock in a transaction on Thursday, September 21st. The stock was sold at an average price of $84.63, for a total value of $84,630,000.00. Following the sale, the director now directly owns 3,928,707 shares in the company, valued at $332,486,473.41. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Stephen W. Webster sold 10,000 shares of the company’s stock in a transaction on Thursday, November 16th. The shares were sold at an average price of $70.14, for a total value of $701,400.00. Following the completion of the sale, the chief financial officer now owns 12,500 shares in the company, valued at $876,750. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 1,068,809 shares of company stock worth $89,809,385. 7.30% of the stock is currently owned by company insiders.

A number of large investors have recently made changes to their positions in ONCE. Teachers Advisors LLC grew its position in Spark Therapeutics by 1.9% in the first quarter. Teachers Advisors LLC now owns 34,534 shares of the biotechnology company’s stock valued at $1,842,000 after acquiring an additional 650 shares during the period. Russell Investments Group Ltd. grew its position in Spark Therapeutics by 81.6% in the second quarter. Russell Investments Group Ltd. now owns 25,228 shares of the biotechnology company’s stock valued at $1,507,000 after acquiring an additional 11,335 shares during the period. Schwab Charles Investment Management Inc. grew its position in Spark Therapeutics by 8.2% in the second quarter. Schwab Charles Investment Management Inc. now owns 94,920 shares of the biotechnology company’s stock valued at $5,671,000 after acquiring an additional 7,169 shares during the period. DekaBank Deutsche Girozentrale bought a new stake in Spark Therapeutics in the second quarter valued at $829,000. Finally, Rhumbline Advisers grew its position in Spark Therapeutics by 16.0% in the second quarter. Rhumbline Advisers now owns 26,278 shares of the biotechnology company’s stock valued at $1,570,000 after acquiring an additional 3,626 shares during the period. Hedge funds and other institutional investors own 94.94% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Cantor Fitzgerald Reiterates $105.00 Price Target for Spark Therapeutics (ONCE)” was published by Community Financial News and is the property of of Community Financial News. If you are reading this piece on another website, it was illegally stolen and republished in violation of United States & international copyright & trademark legislation. The legal version of this piece can be accessed at https://www.com-unik.info/2017/12/14/cantor-fitzgerald-reiterates-105-00-price-target-for-spark-therapeutics-once.html.

About Spark Therapeutics

Spark Therapeutics, Inc is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial.

Analyst Recommendations for Spark Therapeutics (NASDAQ:ONCE)

Receive News & Ratings for Spark Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit